title: [Arguments for deciding to change treatment in benign prostatic hyperplasia].
abstract: Insufficient efficacy above all, but also the appearance of side effects or the occurrence of complications may motivate a change in the treatment of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (HBP). In terms of efficacy, surgery remains superior to all medical treatments including alphablockers which are the most active. 5-alpha-reductase inhibitors have a slow efficacy which is all the more marked when the prostatic volume is large. Phytotherapy has a slight activity which is higher than that of placebo. Drug combinations are currently being studied and, although a benefit has been shown in certain publications, their clinical efficacy remains to be specified. They may become an alternative in case of failure of single-agent therapy to prevent or delay surgery. The incidence of side effects is low and varies with the treatment used and within a same therapeutic class. With alphablockers for instance, orthostatic hypotension, which is the main side effect, varies from 1% to 8% approximately depending on the study and molecule. The side effects of 5-alpha-reductase inhibitors are mainly sexual disorders, observed in 1 to 4% of cases approximately. Hence, the occurrence of a drug side effect causing treatment discontinuation should incite a change of molecule, even within the same class for alphablockers. On the other hand, if complications of HBP occur, it is then necessary to resort to surgery.
authors.affiliation: Clinique Saint-Grégoire, 18, rue Groison, 37100 Tours, France. jc.baron@wanadoo.fr
authors.forename: J C
authors.initials: JC
authors.lastname: Baron
authors.forename: F
authors.initials: F
authors.lastname: Rousselot
mesh_terms: D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000150:complications / Q000628:therapy*; D013812:Therapeutics / Q000009:adverse effects; D017211:Treatment Failure